)
Visual
test
Kyowa Kirin
Kyowa Kirin (4151) investor relations material
Kyowa Kirin Investor update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor update summary1 Feb, 2026
Strategic update and program transition
Regains global control of rocatinlimab development and commercialization after termination of the Amgen partnership, following Amgen's portfolio reprioritization.
Amgen will provide transitional long-term manufacturing and supply support during the handover period.
Kyowa Kirin will lead all development, regulatory, and commercial activities globally, including in Japan, US, Europe, and Asia.
Clinical progress and efficacy
All eight Phase 3 ROCKET studies met primary and key secondary endpoints, including significant improvement in the rIGA score at week 24.
Safety profile in adolescent and adult trials remains consistent, with low discontinuation rates due to adverse events.
Rocatinlimab targets OX40 receptor on pathogenic T cells, offering a novel mechanism for atopic dermatitis and potential expansion to other inflammatory diseases.
Market opportunity and unmet needs
Moderate-to-severe atopic dermatitis remains a high-burden, under-treated condition with significant unmet medical needs.
Only 10-15% of eligible patients currently receive biologic treatment, indicating substantial market growth potential.
US biologic penetration is 15-20%, with projected sales growth over 15% and a 75% increase in advanced therapy-treated population by 2030.
Quantify 2026-2027 P&L impact from Rocatinlimab
Rocatinlimab's differentiation in crowded OX40/AD market
Long-term manufacturing plan post-Amgen transition
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 032640
Net income surged 61.9% year-over-year, with strong wireless and enterprise growth. - LOT
A$76M equity raise supports Kayelekera ramp-up and Letlhakane development amid strong uranium demand. - SYM
Revenue up 29% to $630M, net income $13.36M, $22.3B backlog, strong cash, legal risks persist. - BPT
H1 FY26 revenue hit AUD 1B, with strong gas prices and LNG cargoes driving results. - CPAY
2026 guidance targets 16% revenue and 22% adjusted EPS growth, led by strong Corporate Payments. - TENB
Record 2025 results with double-digit growth, strong cash flow, and expanding AI-driven platform. - DHX
Q4 2025 revenue down 10% YoY; FY 2026 guidance targets $118M–$122M revenue. - COHR
Q2 FY26 revenue up 17% to $1.69B, with strong EPS growth and robust datacenter demand. - ALGT
Q4 2025 saw record results and margin growth, with 2026 outlook boosted by Sun Country deal. - STC
Record bookings, strong cash flow, and margin expansion drive improved outlook.
Next Kyowa Kirin earnings date
Q4 202510 Feb, 2026
Kyowa Kirin
Next Kyowa Kirin earnings date
Q4 202510 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Kyowa Kirin Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and marketing of biopharmaceutical and pharmaceutical products. The company focuses on therapeutic areas including oncology, nephrology, immunology, and the central nervous system, aiming to address complex medical needs. Kyowa Kirin leverages biotechnology and antibody research to develop treatments for patients globally, with products available through prescription channels and hospital networks. The company is headquartered in Tokyo, Japan, and its shares are listed on the TSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage